ALK-Abelló's ACARIZAX trial in China hits primary efficacy targets, strengthening the company's expansion strategy in partnership with GenSci to address a massive, underpenetrated allergy market.
ALK-Abelló reported positive phase 3 trial results for its ACARIZAX tablet in China, successfully meeting the primary endpoint with a 19.1% relative treatment difference in TCRS. These results confirm the drug's efficacy and safety in the Chinese population, providing the necessary clinical data to support upcoming regulatory approval filings. While the trial is a significant milestone, the company noted that these results do not impact its 2026 financial guidance.
The primary endpoint was the average daily total combined rhinitis score (TCRS) during the last 4 weeks of the 24-28 week treatment period.
No, the company explicitly stated that the trial results do not affect its financial guidance for 2026.
As ALK's strategic partner in China, GenSci is positioned to integrate ACARIZAX into its existing biopharmaceutical portfolio upon receiving local regulatory approval. The positive phase 3 trial results significantly de-risk the commercialization path for this product in a market with over 100 million house dust mite allergy sufferers. This partnership leverages GenSci's established presence in the Chinese market to address a currently underpenetrated therapeutic area.
GenSci will add ACARIZAX to its portfolio under a partnership agreement announced in September 2025, pending regulatory approval.
China has the highest number of house dust mite allergy sufferers globally, with over 100 million affected and less than 1 million currently receiving immunotherapy.
ALK-Abelló announced successful phase 3 trial results for its ACARIZAX house dust mite tablet in China, meeting primary endpoints with a 19.1% relative improvement in rhinitis scores. The study, involving 327 participants, confirms the treatment's safety and efficacy, paving the way for regulatory approval in the world's largest market for dust mite allergies.
The trial provides the necessary clinical data to support regulatory approval in China, a critical market where the allergy immunotherapy sector is currently underpenetrated.
The company stated that these trial results do not affect its existing financial guidance for 2026.